AL58805

Study the tolerance and safety of AL58805 after single and multiple administrations in patients with advanced solid tumors, observe the DLT and MTD of the human body after administration, the reversibility of toxicity, and the relationship between toxicity and dose. Study and analyze the pharmacokinetic characteristics of AL58805 tablets in patients with advanced solid tumors. Recommend appropriate dosage and regimen for Phase II clinical trials based on Phase I tolerance and pharmacokinetic results; preliminarily evaluate the efficacy of AL58805 in patients with advanced solid tumors.

Main objectives: (1) To study the tolerance and safety of AL58805 after single and multiple administrations in patients with advanced solid tumors, to observe the dose-limiting toxicity (DLT) and maximum tolerated dose (MTD) in humans after administration, the reversibility of toxicity, and the relationship between toxicity and dose. (2) To study and analyze the pharmacokinetic characteristics of AL58805 tablets in patients with advanced solid tumors. Secondary objectives: 1) To recommend appropriate dosage and regimen for Phase II clinical trials based on the results of Phase I tolerance tests and pharmacokinetic studies; 2) To preliminarily evaluate the efficacy of AL58805 in patients with advanced solid tumors.